United States - English - NLM (National Library of Medicine)

eugia us llc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 60 mg in 20 ml - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine injection [see warnings and precautions (5.7)] pregnancy category c . animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed. it is not known whether adenosine injection is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine injection in nursing infants, the decision to interrupt nursing after administration of adenosine injection or not to administer adenosine injection, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenocard (adenosine injection) is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenocard administration. it is important to be sure the adenocard solution actually reaches the systemic circulation (see dosage and administration). adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenocard administration. intravenous adenocard (adenosine injection) is contraindicated in:

United States - English - NLM (National Library of Medicine)

hospira, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed. it is not known whether adenosine injection is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine injection in nursing infants, the decision to interrupt nursing after administration of adenosine injection or not to administer adenosine injection, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome).  when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration ). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. intravenous adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. intravenous adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patient

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine);   - solution for injection - 6 mg/2ml - active: adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine)   excipient: sodium chloride water for injection - adenocor is indicated for rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome), and as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias, and in sensitisation of intracavity electrophysiological investigations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy

United States - English - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration.  it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ).1 adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functio